Daniel E. Salazar
Daiichi Sankyo
36 Papers
164 Citations
Daniel E. Salazar is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Prasugrel & Prasugrel Hydrochloride. The author has an hindex of 22, co-authored 36 publications.
Chat about Author
Papers
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Jeffrey I. Weitz,Stuart J. Connolly,Indravadan Patel,Daniel E. Salazar,Shashank Rohatagi,Jeanne Mendell,Helen Kastrissios,Jianqing Jin,Satoshi Kunitada +8 more
TL;DR: The results suggest that in this three-month study, edoxaban 30 or 60 mg qd are safe and well-tolerated.
356
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Daniel E. Salazar,Jeanne Mendell,Helen Kastrissios,Michelle Green,Timothy J. Carrothers,SaeHeum Song,Indravadan Patel,Tomas S. Bocanegra,Elliott M. Antman,Robert P. Giugliano,Satoshi Kunitada,Bruce E Dornseif,Minggao Shi,Masaya Tachibana,Simon Zhou,Shashank Rohatagi +15 more
TL;DR: Exposure-response analysis found that in patients with NVAF, the incidence of bleeding events increased significantly with increasing edoxaban exposure, with steady-state minimum concentration (Cmin,ss) showing the strongest association.
150
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
C. Steven Ernest,David S. Small,Shashank Rohatagi,Daniel E. Salazar,Lars Wallentin,Kenneth J. Winters,Rebecca E. Wrishko +6 more
TL;DR: The clopidogrel PK model included dose as a covariate indicating that a significantly less-than-proportional increase in Clop-AM exposure is expected over the dose range of 75–600 mg, thus, the model-predicted PD response is lower than might be anticipated given an 8-fold difference in dose and lower than that typically achieved following prasugrel 60 mg LD.
57
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
Nagy A. Farid,Christopher D. Payne,C. Steven Ernest,Y. Grace Li,Kenneth J. Winters,Daniel E. Salazar,David S. Small +6 more
TL;DR: The results of this open‐label, multiple‐dose, 2‐period, fixed‐sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP 2B6.
51
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Christopher D. Payne,Ying G. Li,John T. Brandt,Joseph A. Jakubowski,David S. Small,Nagy A. Farid,Daniel E. Salazar,Kenneth J. Winters +7 more
TL;DR: Switching directly from clopidogrel MD to either prasugrel LD or MD was well tolerated and resulted in significantly greater levels of platelet inhibition than a clopIDogrel 75 mg MD.
49